Physician profile
Ashley Sims
NPI 1023769817
$476.66
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.82 · 2022: $22.46 · 2023: $269 · 2024: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.90 | 2023-2024 | |
| Dexcom, INC. | $57.23 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $52.76 | 2023 | Farxiga |
| Merck Sharp & Dohme LLC | $47.51 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $39.39 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $38.34 | 2024 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $32.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.45 | 2024 | Jardiance |
| Vanda Pharmaceuticals INC. | $22.46 | 2022 | |
| Seqirus USA INC | $19.20 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $17.56 | 2024 | Shingrix, Pediarix |
| Actelion Pharmaceuticals US, INC. | $16.19 | 2023 | Uptravi, Opsumit |
| Horizon Therapeutics Plc | $15.06 | 2023 | Krystexxa |
| Tris Pharma INC | $15.05 | 2023 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $13.74 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.